Cassava Sciences
We have no price for Cassava Sciences since 11 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Cassava Sciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cassava Sciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Cassava Sciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 12, 2026 | -0.26 | -0.30 | +13.5% |
| Nov 12, 2025 | -0.22 | -0.27 | +18.5% |
| Aug 14, 2025 | -0.18 | – | – |
| May 8, 2025 | -0.48 | – | – |
| Mar 3, 2025 | -0.57 | -0.68 | +16.2% |
| Nov 7, 2024 | -0.58 | -1.37 | +57.7% |
| Aug 8, 2024 | -1.28 | -0.44 | −190.9% |
| May 10, 2024 | -1.41 | -0.51 | −176.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about Cassava Sciences
Is Cassava Sciences a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cassava Sciences AI analysis
What does Cassava Sciences do?
Cassava Sciences, Inc. is a biopharmaceutical enterprise in the clinical development phase, specializing in the creation of treatments for neurodegenerative disorders. It is in Biotechnology.
Who are Cassava Sciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Cassava Sciences's.
Prices: daily closes to Jun 11, 2026. Fundamentals: company reports via invest-like data.